In summary, our findings uncover that the TGs hyperproduction may partake in the metabolic dysregulation underlying COVID-19 pathogenesis and provides the basis for further development of DGAT-targeting and ADRP-targeting interventions for COVID-19 therapeutics. The gene discussed is DGAT1; the disease is COVID-19.